Abstract:Xiao-Bei Si, 1, 2 Ling-Yun Zhang, 2 Shuo Yang, 3 Xiao-Lu Chen, 2 Yan-Yan Shi, 4 Yu Lan, 2 Shi-Gang Ding 1 1 Department of Gastroenterology, Peking University Third Hospital, Beijing, People's Republic of China; 2 Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People's Republic of China; 3 Department of Pharmacy, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People's Republic of China; 4 Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, People's Republic of China Correspondence: Shi-Gang Ding, Department of Gastroenterology, Peking University Third Hospital, Beijing, People's Republic of China, Email Yu Lan, Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People's Republic of China, Email Background: Minocycline, a derivative of tetracycline, has anti- Helicobacter pylori ( H. pylori ) properties and can be used to treat H. pylori infection. However, only a few randomized controlled trials (RCTs) have investigated the efficacy of minocycline-containing quadruple therapy (MCQT) in treating H. pylori infection. This study aimed to determine the efficacy and safety of MCQT and investigate the factors influencing both aspects. Methods: This was a retrospective cohort study. Patients diagnosed with H. pylori infection between January 1, 2022, and July 31, 2023 at. The primary outcome was the eradication rate of H. pylori , and the secondary outcome was the number and type of adverse events. Results: A total of 828 patients were included in this study. The overall H. pylori eradication rate among the included patients at 95% confidence interval (CI) (Range 0.864 to 0.907) was 88.53%. The H. pylori eradication rate for patients who received MCQT regimen as the primary therapy was 92.28% (95% CI: 0.901– 0.945), significantly higher than that of patients who received MCQT as rescue therapy (80.81%; 95% CI: 0.761– 0.855, P= 0.003). Adverse events, including dizziness, abdominal distension, diarrhea, nausea, abdominal discomfort, constipation, headache, rash, sleep disorder, palpitation, backache, and anorexia, occurred in 185 (22.34%) patients, with dizziness being the most common (75/828, 9.06%). Compliance with MCQT therapy was an independent factor influencing H. pylori eradication in patients receiving MCQT as a primary therapy. Compliance and presence or absence of H. pylori infection symptoms at the time of screening were independent factors influencing H. Pylori eradication in patients receiving MCQT as rescue therapy. Factors that influenced the occurrence of adverse events included reasons for H. pylori infection screening, residence, treatment compliance, and the use of acid-suppressant regimens. Conclusion: MCQT regimens were effective in H. pylori infection eradication, and the treatment resulted only in fewer adverse events when used as primary or rescue therapies for H. pylori infection treatment. Future prospective studies with larger sample sizes and more comprehensive data are needed to validate our findings. Keywords: Helicobacter pylori , minocycline, cohort study Helicobacter pylori ( H. pylori ) is a gram-negative, microaerophilic bacterium that colonizes human gastric mucosa. 1 H. pylori causes many diseases, including chronic gastritis, gastric and duodenal ulcers, mucosa-associated lymphoid tissue development, and gastric adenocarcinoma. 2 Currently, triple therapy (proton-pump inhibitor combined with two antibiotics) and bismuth quadruple therapy (proton-pump inhibitor, bismuth, and two antibiotics) are used globally to treat H. pylori infection. 3 China is one of the countries with the highest clarithromycin resistance rates in the world. 4 Accordingly, bismuth quadruple therapy has been recommended over triple therapy for initial and second-line H. pylori treatment. However, triple therapy is the currently recommended treatment for H. pylori . 4 Several studies have shown that the efficacy of BCQT against H. pylori infection has gradually decreased 3 in past decades, with antibiotic resistance implicated as one of the main resources. 5 In 2022, Chinese national clinical practice guideline 4 on H. pylori treatment recommended high-dose dual therapy (HDDT), a new, improved therapy consisting of amoxicillin (≥3.0 g/day) and PPIs (double dose twice per day o -Abstract Truncated-

Application of Minocycline-Containing Bismuth Quadruple Therapies As First-Line Regimens in the Treatment of Helicobacter Pylori.

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Minocycline/Amoxicillin-Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Pilot Study

Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.

Erratum to: Divergent Responses of Soil Fungi Functional Groups to Short-term Warming

Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection

Ten-Day Bismuth-Containing Quadruple Therapy is Effective As First-Line Therapy for Helicobacter Pylori-Related Chronic Gastritis: A Prospective Randomized Study in China

New regimens as first‐line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial

Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study

Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial

The Efficacy and Safety of Minocycline‐Containing Quadruple Therapies Against Helicobacter pylori Infection: A Retrospective Cohort Study

Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori

A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating Helicobacter pylori-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China

Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection

Esomeprazole, Minocycline, Metronidazole and Bismuth As First-Line and Second-Line Regimens for Helicobacter Pylori Eradication

Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication:a perspective, multicenter, randomized controlled trial

A Clinical Study of Proton Pump Inhibitor-containing Quadruple Regimen as First-line Therapy for Helicobacter pylori Eradication

Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs

Non-bismuth Quadruple Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication: a Randomized Controlled Study

Identification of Reticulitermes spp. (Isoptera: Reticulitermatidae) from south central United States by PCR-RFLP.

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori